Cistanoside BCAS# 93236-41-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 93236-41-0 | SDF | Download SDF |
PubChem ID | 13880459 | Appearance | Powder |
Formula | C37H50O20 | M.Wt | 814.8 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [5-hydroxy-6-[2-(4-hydroxy-3-methoxyphenyl)ethoxy]-2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate | ||
SMILES | CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)OC)COC4C(C(C(C(O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)OC)O)O)O)O | ||
Standard InChIKey | XSSFBGUVLPAGRS-RMKNXTFCSA-N | ||
Standard InChI | InChI=1S/C37H50O20/c1-16-26(42)28(44)31(47)37(53-16)57-34-32(48)36(51-11-10-18-5-8-20(40)22(13-18)50-3)55-24(15-52-35-30(46)29(45)27(43)23(14-38)54-35)33(34)56-25(41)9-6-17-4-7-19(39)21(12-17)49-2/h4-9,12-13,16,23-24,26-40,42-48H,10-11,14-15H2,1-3H3/b9-6+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Cistanoside B Dilution Calculator
Cistanoside B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.2273 mL | 6.1365 mL | 12.273 mL | 24.5459 mL | 30.6824 mL |
5 mM | 0.2455 mL | 1.2273 mL | 2.4546 mL | 4.9092 mL | 6.1365 mL |
10 mM | 0.1227 mL | 0.6136 mL | 1.2273 mL | 2.4546 mL | 3.0682 mL |
50 mM | 0.0245 mL | 0.1227 mL | 0.2455 mL | 0.4909 mL | 0.6136 mL |
100 mM | 0.0123 mL | 0.0614 mL | 0.1227 mL | 0.2455 mL | 0.3068 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6-hydroxyapigenin-6-O-β-D-glucoside-7-O-β-D-glucuronide
Catalog No.:BCN0924
CAS No.:1146045-40-0
- Cucurbitacin J
Catalog No.:BCN0923
CAS No.:5979-41-9
- Cucurbitacin K
Catalog No.:BCN0922
CAS No.:6766-43-4
- Cucurbitacin O
Catalog No.:BCN0921
CAS No.:25383-23-7
- Cucurbitacin P
Catalog No.:BCN0920
CAS No.:25383-26-0
- Cucurbitacin L
Catalog No.:BCN0919
CAS No.:1110-02-7
- Cucurbitacin F
Catalog No.:BCN0918
CAS No.:5939-57-1
- Cucurbitacin H
Catalog No.:BCN0917
CAS No.:751-95-1
- Cucurbitacin C
Catalog No.:BCN0916
CAS No.:5988-76-1
- Cinnamtannin D2
Catalog No.:BCN0915
CAS No.:97233-47-1
- Cinnamtannin D1
Catalog No.:BCN0914
CAS No.:97233-06-2
- Cinnamtannin B2
Catalog No.:BCN0913
CAS No.:88038-12-4
- Purpureaside B
Catalog No.:BCN0926
CAS No.:104777-69-7
- Jionoside C
Catalog No.:BCN0927
CAS No.:120406-33-9
- Polygalasaponin B
Catalog No.:BCN0928
CAS No.:103444-92-4
- polygalasaponin Ⅰ
Catalog No.:BCN0929
CAS No.:162901-83-9
- Polygalasaponin XXXII
Catalog No.:BCN0930
CAS No.:176182-04-0
- Pelargonidin 3-O-Arabinoside
Catalog No.:BCN0931
CAS No.:724434-09-7
- Apigenin-7-O-sophroside
Catalog No.:BCN0932
CAS No.:52073-83-3
- 1-Propanone, 1-(4-hydroxyphenyl)-3-(2,4,6-trihydroxyphenyl)-
Catalog No.:BCN0933
CAS No.:87095-86-1
- Cyanidin 3-glucopyranosyl-(1→6)-[3-xylopyranosyl-(1→2)]-galactopyranoside
Catalog No.:BCN0934
CAS No.:142561-98-6
- Cyanidin 3-xylosyl-(sinapoyl-glucosyl)-galactoside
Catalog No.:BCN0935
CAS No.:142630-71-5
- Cyanidin 3-xylosyl-(feruloyl-glucosyl)-galactoside
Catalog No.:BCN0936
CAS No.:142561-99-7
- Cyanidin 3-xylosyl-(coumaroyl-glucosyl)-galactoside
Catalog No.:BCN0937
CAS No.:142506-21-6
Chemical profiles and metabolite study of raw and processed Cistanche deserticola in rats by UPLC-Q-TOF-MS(E).[Pubmed:34583715]
Chin Med. 2021 Sep 28;16(1):95.
BACKGROUND: Chinese materia medica processing is a distinguished and unique pharmaceutical technique in Traditional Chinese Medicine (TCM) used for reducing side effects, and increasing or even changing therapeutic efficacy of the raw herbs.Changes in the essential components induced by an optimized processing procedure are primarily responsible for the increased efficacy of medicinal plants.The kidney-yang invigorating effect of rice wine-steamed Cistancha deserticola (C. deserticola) was stronger than raw C. deserticola (CD). METHODS: A comparison analysis was carried out using the UPLC-Q-TOF-MS(E) with the UNIFI informatics platform to determine the influence of processing. In vitro studies were performed for the characterization of constituents as well as metabolites in vivo. The chemical components were determined in CD and its processed products. The multivariate statistical analyses were conducted to evaluate variations between them while OPLS-DA was used for pairwise comparison. RESULTS: The results of this study revealed considerable variations in phenylethanoid glycosides (PhGs) and iridoids after processing. A total of 97 compounds were detected in the extracts of CD and its processed product. PhGs having 4'-O-caffeoyl group in the 8-O-beta-D-glucopyranosyl part, like acteoside, cistanoside C, campneoside II, osmanthuside decreased after being processed, while PhGs with 6'-O-caffeoyl group in the 8-O-beta-D-glucopyranosyl part, such as isoacetoside, isocistanoside C, isocampneoside I, isomartynoside increased, especially in the CD-NP group. The intensity of echinacoside and Cistanoside B whose structure possess 6'-O-beta-D-glucopyranosyl moiety also increased. In in vivo study, 10 prototype components and 44 metabolites were detected in rat plasma, feces, and urine. The obtained results revealed that processing leads to the considerable variation in the chemical constituents of CD and affected the disposition of the compounds in vivo, and phase II metabolic processes are the key cascades of each compound and most of the metabolites are associated with echinacoside or acteoside. CONCLUSIONS: This is the first global comparison research of raw and processed CD. These findings add to our understanding of the impact of CD processing and give important data for future efficacy investigations.
Rapid screening and identification of the differences between metabolites of Cistanche deserticola and C. tubulosa water extract in rats by UPLC-Q-TOF-MS combined pattern recognition analysis.[Pubmed:27639339]
J Pharm Biomed Anal. 2016 Nov 30;131:364-372.
Cistanches Herba is a famous traditional Chinese medicine that has been in use for treating kidney deficiency, impotence, female infertility, morbid leucorrhea, profuse metrorrhagia, and senile constipation. With the exception of studies available for a few single active ingredients such as echinacoside, acteoside, and poliumoside, comprehensive and systematic studies on in vivo metabolism of Cistanches Herba are lacking despite its widespread clinical application. There is no comparative study yet on the metabolites resulting from the traditional usage of Cistanche deserticola and C. tubulosa water extract - two species that are recorded in Chinese Pharmacopoeia. This further restricts research on the therapeutic effect of Cistanches Herba to a great extent. In this study, a robust and unbiased UPLC-Q-TOF-MS combined pattern recognition analysis (orthogonal partial least squared discriminant analysis, OPLS-DA) was employed to rapidly screen prototype components and metabolites of C. deserticola and C. tubulosa water extract in rat urine, feces, and serum. A total of 71 metabolites from C. deserticola including 25 prototype components and 46 metabolites, and 45 metabolites from C. tubulosa including 18 prototype components and 27 metabolites were tentatively identified. Out of these, 10 metabolites were characterized for the first time in these two species. Results of this study indicate that phenylethanoid glycosides (PhGs) are mainly metabolized into degradation products in the gastrointestinal tract of rats. The chemical components Cistanoside B, C, D, and E exist only in C. deserticola and release methylated hydroxytyrosol (HT) following metabolism. This factor contributes to the difference between metabolites of C. deserticola and C. tubulosa water extract in rats and is responsible for the differential therapeutic effect that these two species of Cistanches Herba have on the same diseases.
[Study the chemical constituents from Phlomis mongolica turcz].[Pubmed:12205971]
Zhongguo Zhong Yao Za Zhi. 2000 Jan;25(1):35-7.
OBJECTIVE: To investigate the chemical constituents from the root of Phlomis mongolica. METHOD: The chemical constituents were extracted with solvent and separated with chromatographic methods. Three compounds were obtained and identified by MS, 1H-NMR, 13C-NMR, DEPT, HMQC and HMBC methods. RESULT: The structures were established as phloyoside III, phloyoside I and Cistanoside B. CONCLUSION: These compounds were obtained from P. mongolica for the first time. Phloyoside III is a new compound.